SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

ALX Oncology Reports Q3 2026 Net Loss of $21.8 Million, Cash of $147.2 Million

ALX Oncology reported a third-quarter 2026 GAAP net loss of $21.8 million, or $0.15 per share, compared with a $22.1 million loss a year earlier. Cash, cash equivalents and investments totaled $147.2 million at September 30, 2026, which the company expects to fund planned operations through the fir…

ALXO

Related stories